WHO Drug Information Vol. 19, No. 2, 2005
(2005; 98 pages)

Table of Contents

Biomedicines Update
	International nomenclature and gene therapy products
Safety and Efficacy Issues
	Tiagabine: seizures in patients without a history of epilepsy
	Effect of medroxyprogesterone on bone mineral density
	Tumour necrosis factor inhibitors: safety update
	Pimecrolimus and tacrolimus linked to cancer increase
	Erythropoietin: caution in cancer patients
	Oxcarbazepine: multi-organ hypersensitivity
	Drotrecogin alfa: single organ dysfunction
	Drotrecogin alfa: not indicated for paediatric sepsis
	Interferon beta-1 a and hepatic injury
	Avascular necrosis with interferon alfa-2b in chronic myelogenous leukaemia
	Hylan G-F 20: joint inflammation and pain
	Galantamine and vascular events
	Rosuvastatin: revised start doses
	New kidney function test a better predictor of risk
	Statins and peripheral neuropathy
	Angioedema: still a problem with ACE inhibitors
	More advice on SSRI use
	Million Women Study: latest HRT data
	Tuberculin purified protein derivative (Mantoux) and serious allergic reactions
	Ezetimibe: hepatic, muscle, and pancreatic reactions
	Mefloquine: revised patient information
	Atomoxatine and liver injury
	Gefitinib: failure to show survival in lung cancer
Regulatory Action and News
	Progress on defining borderline pharmaceutical products
	Temozolomide approved for glioblastoma multiforme
	Pramlintide approved for diabetes
	Entecavir approved for chronic hepatitis B
	DNA-based test approved to detect cystic fibrosis
	Nataluzimab: marketing withdrawal pending evaluation
	Rosiglitazone (Nyracta®): voluntary withdrawal
	Risk management legislation
	New pharmacogenomics guidance
Current Topics
	WHO clinical trial registration initiative
	International registration of trial information: Ottawa statement
	Disclosure of information on clinical trials
	Forecasting antiretroviral and diagnostic needs
ATC/DDD classification
	Temporary list
	Final list
Recent Publications and Sources of Information
	Sources and prices of malaria medicines and products
	Launch of a searchable online database of adverse reactions
	Newly-published European Union guidelines
The International Pharmacopoeia
	Monographs for antiretrovirals
		Lamivudine (first draft)
		Nelfinavir mesilate oral powder (first draft)
		Nelfinavir mesilate tablets (first draft)
		Saquinavir mesilate capsules (first draft)
		Stavudine (first draft)
		Zidovudine (first draft)
International Nonproprietary Names for Pharmaceutical Substances (INN)

WHO Drug Information Vol. 19, No. 2, 2005

WHO Drug Information
e-mail table of contents &
subscriptions
available at:
http://www.who.int/druginformation